Sanofi (SNY)
(Delayed Data from NSDQ)
$56.26 USD
-0.07 (-0.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.24 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.26 USD
-0.07 (-0.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.24 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study
What's in the Cards for Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2020 results.
Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.
Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.
What's in Store for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.
Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?
by Zacks Equity Research
On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.
Why Sanofi (SNY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease
by Zacks Equity Research
Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.
Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.
Top Analyst Reports for Netflix, AstraZeneca & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), AstraZeneca (AZN) and Union Pacific (UNP).
What To Expect From The Crazy Earnings Season Ahead
by Daniel Laboe
Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners
by Tirthankar Chakraborty
As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.
FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus
by Ritujay Ghosh
Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
by Zacks Equity Research
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing